These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23307541)

  • 1. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.
    Davies-Vorbrodt S; Ito JI; Tegtmeier BR; Dadwal SS; Kriengkauykiat J
    Pharmacotherapy; 2013 Jan; 33(1):22-30. PubMed ID: 23307541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effect of obesity on voriconazole serum concentrations.
    Koselke E; Kraft S; Smith J; Nagel J
    J Antimicrob Chemother; 2012 Dec; 67(12):2957-62. PubMed ID: 22915462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
    Trifilio S; Pennick G; Pi J; Zook J; Golf M; Kaniecki K; Singhal S; Williams S; Winter J; Tallman M; Gordon L; Frankfurt O; Evens A; Mehta J
    Cancer; 2007 Apr; 109(8):1532-5. PubMed ID: 17351937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
    Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
    Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
    Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
    Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
    Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The obesity paradox, weight loss, and coronary disease.
    Lavie CJ; Milani RV; Artham SM; Patel DA; Ventura HO
    Am J Med; 2009 Dec; 122(12):1106-14. PubMed ID: 19682667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
    Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
    J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
    Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K; Tallman MS; Evens A; Scheetz MH; Blum W; Kontoyiannis DP
    Bone Marrow Transplant; 2007 Apr; 39(7):425-9. PubMed ID: 17310132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary antiphospholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism.
    Gary T; Belaj K; Bruckenberger R; Hackl G; Hafner F; Froehlich H; Zebisch A; Pilger E; Brodmann M
    Obesity (Silver Spring); 2013 Sep; 21(9):E463-6. PubMed ID: 23671009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
    Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
    Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
    Navarro WH; Loberiza FR; Bajorunaite R; van Besien K; Vose JM; Lazarus HM; Rizzo JD
    Biol Blood Marrow Transplant; 2006 May; 12(5):541-51. PubMed ID: 16635789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
    Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
    Spinler SA; Ou FS; Roe MT; Gibler WB; Ohman EM; Pollack CV; Alexander KP; Peterson ED
    Pharmacotherapy; 2009 Jun; 29(6):631-8. PubMed ID: 19476416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.